Drug Trial Radar · NCT01948193
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth
Last checked: Nov 19, 2026Latest source record: Oct 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
177
Actual
Start
Feb 2014
Primary completion
Dec 2014
Study completion Jun 2015
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 23, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 weeks, up to 8 weeks
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to describe the immunogenicity and safety of a novel DTaP- IPV- Hep B-PRT\~T fully liquid combined hexavalent vaccine (Hexaxim™) administered at 6, 10 and 14 weeks of age in infants born to mothers documented to be serum anti-hepatitis B surface antigen (HBsAg) serology negative in India. Primary Objective: * To evaluate the immunogenicity of the study vaccine in terms of seroprotection \[diphtheria toxoid, tetanus toxoid, poliovirus types 1, 2 and 3, Haemophilus influenzae type b (Hib) polysaccharide (PRP), hepatitis B (Hep B)\] and vaccine response for pertussis antigens \[pertussis toxoid (PT) and filamentous haemagglutinin (FHA)\] one month after the third dose. Secondary Objectives: * To further describe the immunogenicity of the study vaccine, before the first dose and one month after the third dose. * To describe the safety after each and any doses of the study vaccine.
Conditions
- Diphtheria
- Tetanus
- Whooping Cough
- Hepatitis B
- Poliomyelitis
- Invasive Hib Infections
Interventions
Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccineBiological
0.5 mL, Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Seroprotection After Vaccinations With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Following a Documented Dose of a Commercial Oral Poliovirus Vaccine and Recombinant Hep B Monovalent Vaccine at BirthTime frame: Pre-dose 1 to one month post-dose 3
- Percentage of Participants With Vaccine Response After Vaccinations With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Following a Documented Dose of a Commercial Oral Poliovirus Vaccine and Recombinant Hep B Monovalent Vaccine at BirthTime frame: Pre-dose 1 to one month post-dose 3
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Pune, India
Site not named
Ludhiana, Punjab, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.